Quibim, a Spanish startup at the forefront of developing foundational AI models for medical imaging, has successfully raised $50 million in a Series A funding round. This significant investment comes as artificial intelligence continues to make profound inroads into the healthcare sector, impacting everything from drug discovery to clinical trials.
Enhancing Diagnostic Accuracy
Quibim is on a mission to improve diagnostic accuracy and disease detection through visual data obtained from X-rays, CT scans, and MRIs. Their flagship product, QP-Prostate, is specifically designed to enhance prostate cancer detection, with additional products in development for other critical areas, including the brain, liver, breast, and lung.
In addition to its imaging solutions, Quibim offers QP-Insights, a tool for processing multi-omics data, which integrates various biological data types for use in clinical trials and related studies. This dual approach positions Quibim as a key player in the evolving landscape of precision health.
A Vision for Digital Twins
Looking ahead, Quibim aims to create digital twins of the entire human body, developing “dynamic models” that will enable the medical community to gain deeper insights into human health. This ambitious vision begins at the organ and lesion level, as demonstrated by their work with QP-Prostate.
Expansion Plans in the U.S.
With this latest funding, Quibim plans to accelerate its expansion into the U.S. market. The company received FDA 510(k) clearance in 2023 to market its QP-Prostate product and has recently appointed its first chief medical officer in the U.S. Currently, Quibim boasts 170 installations globally, with partnerships that include prestigious institutions such as Stanford University and the Mass General Brigham healthcare system.
The Series A round was led by Spanish venture capital firm Asabys and private equity firm Buenavista, with participation from a range of institutional and individual investors, including Amadeus Capital Partners, Apex Ventures, Partech, and Tony Fadell, co-creator of the iPod and iPhone.
A Commitment to Precision Health
“Quibim’s mission is to turn imaging into a catalyst for precision health,” said Ángel Alberich-Bayarri, CEO and co-founder of Quibim. “Our global expansion into the U.S. is a critical milestone as we work with pharmaceutical leaders and healthcare providers to unlock the power of imaging to revolutionize diagnostics and improve patient outcomes.”
As Quibim continues to innovate and expand, the potential for AI-driven advancements in medical imaging is vast, promising to enhance patient care and outcomes in the years to come.